"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents inhibiting the effect of narcotics on the central nervous system.
| Descriptor ID |
D009292
|
| MeSH Number(s) |
D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
|
| Concept/Terms |
Narcotic Antagonists- Narcotic Antagonists
- Antagonists, Narcotic
- Opioid Receptor Antagonists
- Antagonists, Opioid Receptor
- Receptor Antagonists, Opioid
- Opioid Antagonists
- Antagonists, Opioid
|
Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".
This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 2 | 4 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 4 | 1 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 4 | 0 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 2 | 6 |
| 2014 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 4 | 2 | 6 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 4 | 8 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
| 2025 | 3 | 2 | 5 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.
-
Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas. J Addict Med. 2020 12; 14(6):e372-e374.
-
A Transcriptome-Based Drug Discovery Paradigm for Neurodevelopmental Disorders. Ann Neurol. 2021 02; 89(2):199-211.
-
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology. 2020 09; 45(10):1656-1663.
-
Preparations for Treating Opioid Use Disorder in the Office. Fam Pract Manag. 2018 Nov/Dec; 25(6):21-26.
-
Buprenorphine Therapy for Opioid Use Disorder. Am Fam Physician. 2018 Mar 01; 97(5):313-320.
-
Buprenorphine Prescribing: To Expand or Not to Expand. J Psychiatr Pract. 2016 05; 22(3):183-92.
-
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan; 19(1):110-20.
-
Electroacupuncture suppresses capsaicin-induced secondary hyperalgesia through an endogenous spinal opioid mechanism. Pain. 2009 Oct; 145(3):332-340.
-
Adenylyl cyclase-5 activity in the nucleus accumbens regulates anxiety-related behavior. J Neurochem. 2008 Oct; 107(1):105-15.
-
Distinct inhibition of voltage-activated Ca2+ channels by delta-opioid agonists in dorsal root ganglion neurons devoid of functional T-type Ca2+ currents. Neuroscience. 2008 Jun 02; 153(4):1256-67.